Retrophin Inc. | Ownership
Companies that own Retrophin Inc.
Scopia Capital Management LP
6,519,425
16.13%
-139,741
3.54%
06/30/2018
Consonance Capital Management LP
3,843,371
9.51%
150,000
6.51%
06/30/2018
Perceptive Advisors LLC
3,212,871
7.95%
0
2.31%
06/30/2018
BlackRock Fund Advisors
3,139,835
7.77%
210,444
0.01%
06/30/2018
The Vanguard Group, Inc.
1,821,595
4.51%
94,681
0%
06/30/2018
Macquarie Investment Management Business Trust
1,617,618
4%
177,604
0.1%
06/30/2018
Manulife Asset Management (US) LLC
1,502,557
3.72%
1,487,657
0.07%
06/30/2018
SSgA Funds Management, Inc.
1,451,412
3.59%
189,959
0%
06/30/2018
Fidelity Management & Research Co.
1,089,728
2.7%
0
0%
06/30/2018
Jennison Associates LLC
1,070,327
2.65%
14,166
0.03%
06/30/2018
| Address |
3721 Valley Centre Drive
San Diego California 92130
United States
|
|
Employees
|
- |
| Website |
http://www.retrophin.com |
| Updated |
07/08/2019 |
| Retrophin, Inc. is a biopharmaceutical company, which engages in identifying, developing, and delivering therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. |
